Skip to main content
logo
AstraZeneca PLC (AZN)
NYSE: AZN · Real-Time Price · USD
167.27
+3.32 (2.03%)
Oct 20, 2026, 9:39 AM EDT - Market open

AstraZeneca Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal QuarterQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023Q2 2023Q1 2023Q4 2022Q3 2022Q2 2022Q1 2022Q4 2021Q3 2021
Period EndingJun '26 Mar '26 Dec '25 Sep '25 Jun '25 Mar '25 Dec '24 Sep '24 Jun '24 Mar '24 Dec '23 Sep '23 Jun '23 Mar '23 Dec '22 Sep '22 Jun '22 Mar '22 Dec '21 Sep '21
Revenue
15,38415,28815,50315,19114,45713,58814,89113,56512,93812,67912,02411,49211,41610,87911,20710,98210,77111,39012,0119,866
Revenue Growth
6.41%12.51%4.11%11.99%11.74%7.17%23.84%18.04%13.33%16.55%7.29%4.64%5.99%-4.49%-6.69%11.31%31.03%55.60%62.09%49.98%
Gross Profit
12,85312,61512,33312,39911,98411,34712,73510,48410,75510,4619,9449,3979,4568,97412,0798,0007,7737,87910,0246,109
Operating Income
3,6094,2723,3473,6623,5083,6084,9622,1062,7463,1153,3411,9542,4562,5415,6951,2455391,5243,676-502
Net Income
2,5073,0802,3262,5332,4502,9161,5001,4291,9272,1799601,3741,8181,8039011,640360386-347-1,652
Earnings Per Share
1.611.971.481.621.571.870.960.911.231.400.610.881.171.160.581.050.230.25-0.22-1.10
EPS Growth
2.55%5.35%53.94%78.02%27.64%33.57%56.70%3.41%5.13%20.69%5.88%-16.19%408.70%365.20%---45.13%-78.87%--

Revenue by Segment
Chart
Fiscal QuarterQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023Q2 2023Q1 2023Q4 2022Q3 2022Q2 2022Q1 2022Q4 2021Q3 2021
Period EndingJun '26 Mar '26 Dec '25 Sep '25 Jun '25 Mar '25 Dec '24 Sep '24 Jun '24 Mar '24 Dec '23 Sep '23 Jun '23 Mar '23 Dec '22 Sep '22 Jun '22 Mar '22 Dec '21 Sep '21
Oncology
7,3266,7977,0276,6366,3125,6435,3415,1974,9764,7604,4534,3894,3823,9203,7463,7973,7013,3883,4553,326
BioPharmaceuticals: Cardiovascular, Renal & Metabolism PR (CVRM)
2,7723,2413,0463,2163,2643,2483,1323,1523,1533,0122,6982,6832,6752,5302,2812,3482,3522,2072,0032,082
BioPharmaceuticals: Respiratory & Immunology PR (R&I)
2,4312,3182,3732,2592,1502,0841,9851,8301,7971,8041,5901,4511,4831,5831,4471,4271,3811,5091,5901,483
BioPharmaceuticals Infectious Disease PR (ID)
131182442416185225378355112212345224883551,1298739771,757--
Rare Disease
2,4902,4202,3742,4162,2942,0422,2772,1482,1472,0961,9711,9741,9531,8661,8161,7411,8011,6941,7591,311
Other Medicines
234253235237244272249265267293266297301312379404418425825539
Collaboration
-776118741,529618486502701474534313409392141410513125
Revenue (Total)
15,38415,28815,50315,19114,45713,58814,89113,56512,93812,67912,02411,49211,41610,87911,20710,98210,77111,39012,0119,866

Cash & Debt
Chart
Fiscal QuarterQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023Q2 2023Q1 2023Q4 2022Q3 2022Q2 2022Q1 2022Q4 2021Q3 2021
Period EndingJun '26 Mar '26 Dec '25 Sep '25 Jun '25 Mar '25 Dec '24 Sep '24 Jun '24 Mar '24 Dec '23 Sep '23 Jun '23 Mar '23 Dec '22 Sep '22 Jun '22 Mar '22 Dec '21 Sep '21
Cash & Investments
4,9687,6755,7198,1827,1085,3955,5254,9307,0768,0215,8605,1155,8126,4626,2444,5224,8875,8236,3987,149
Total Debt
32,35034,02929,70332,66132,93931,71730,46031,61333,64534,69429,64929,55330,79432,47231,13531,27531,38832,74533,36334,388
Net Cash (Debt)
-27,382-26,354-23,984-24,479-25,831-26,322-24,935-26,683-26,569-26,673-23,789-24,438-24,982-26,010-24,891-26,753-26,501-26,922-26,965-27,239
Net Cash Growth
--------------------
Net Cash Per Share
-17.55-16.88-15.34-15.68-16.57-16.86-15.96-17.08-17.03-17.10-15.24-15.67-16.01-16.67-15.97-17.16-16.99-17.25-17.43-18.21

Cash Flow & CapEx
Chart
Fiscal QuarterQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023Q2 2023Q1 2023Q4 2022Q3 2022Q2 2022Q1 2022Q4 2021Q3 2021
Period EndingJun '26 Mar '26 Dec '25 Sep '25 Jun '25 Mar '25 Dec '24 Sep '24 Jun '24 Mar '24 Dec '23 Sep '23 Jun '23 Mar '23 Dec '22 Sep '22 Jun '22 Mar '22 Dec '21 Sep '21
Operating Cash Flow
2,8653,3592,3425,1343,3863,7132,9073,3833,0852,4862,3803,1141,7183,1332,3982,9301,2483,2321,4181,719
Capital Expenditures
-763-547-1,036-686-659-429-708-417-382-417-525-319-270-247-372-247-253-219-323-260
Free Cash Flow
2,1022,8121,3064,4482,7273,2842,1992,9662,7032,0691,8552,7951,4482,8862,0262,6839953,0131,0951,459
Free Cash Flow Growth
-22.92%-14.37%-40.61%49.97%0.89%58.72%18.54%6.12%86.67%-28.31%-8.44%4.17%45.53%-4.21%85.02%83.89%64.73%75.79%-23.69%-8.47%

Margins
Chart
Fiscal QuarterQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023Q2 2023Q1 2023Q4 2022Q3 2022Q2 2022Q1 2022Q4 2021Q3 2021
Period EndingJun '26 Mar '26 Dec '25 Sep '25 Jun '25 Mar '25 Dec '24 Sep '24 Jun '24 Mar '24 Dec '23 Sep '23 Jun '23 Mar '23 Dec '22 Sep '22 Jun '22 Mar '22 Dec '21 Sep '21
Gross Margin
83.55%82.52%79.55%81.62%82.89%83.51%85.52%77.29%83.13%82.51%82.70%81.77%82.83%82.49%107.78%72.85%72.17%69.17%83.46%61.92%
Operating Margin
23.46%27.94%21.59%24.11%24.27%26.55%33.32%15.53%21.22%24.57%27.79%17.00%21.51%23.36%50.82%11.34%5.00%13.38%30.61%-5.09%
Pretax Margin
18.19%25.60%16.96%21.35%21.63%25.04%11.19%13.48%18.53%22.08%7.46%14.38%18.29%20.79%6.94%8.40%2.29%4.86%-5.30%-20.28%
Profit Margin
16.30%20.15%15.00%16.67%16.95%21.46%10.07%10.53%14.89%17.19%7.98%11.96%15.93%16.57%8.04%14.93%3.34%3.39%-2.89%-16.74%
FCF Margin
13.66%18.39%8.42%29.28%18.86%24.17%14.77%21.87%20.89%16.32%15.43%24.32%12.68%26.53%18.08%24.43%9.24%26.45%9.12%14.79%

Dividends
Chart
Fiscal QuarterQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023Q2 2023Q1 2023Q4 2022Q3 2022Q2 2022Q1 2022Q4 2021
Period EndingJun '26 Mar '26 Dec '25 Sep '25 Jun '25 Mar '25 Dec '24 Sep '24 Jun '24 Mar '24 Dec '23 Sep '23 Jun '23 Mar '23 Dec '22 Sep '22 Jun '22 Mar '22 Dec '21
Dividend Per Share
1.060-2.170-1.030-2.100-1.000-1.970-0.930-1.970-0.930-1.970
Dividend Per Share Growth
2.91%-3.33%-3.00%-6.60%-7.53%-0%-0%-0%----
Dividend Yield
1.73%-1.72%-2.26%-2.37%-1.90%-2.15%-2.02%-2.15%-2.21%-2.44%

Valuation
Chart
Fiscal QuarterQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023Q2 2023Q1 2023Q4 2022Q3 2022Q2 2022Q1 2022Q4 2021Q3 2021
Period EndingJun '26 Mar '26 Dec '25 Sep '25 Jun '25 Mar '25 Dec '24 Sep '24 Jun '24 Mar '24 Dec '23 Sep '23 Jun '23 Mar '23 Dec '22 Sep '22 Jun '22 Mar '22 Dec '21 Sep '21
PE Ratio
27.7828.9628.1524.8025.9229.0128.8837.0737.5933.0235.1435.6136.0445.7863.7284.20----
P/FCF Ratio
27.2026.6424.4618.4119.2420.2220.4525.1025.6925.6023.2922.9424.5625.0724.0322.0530.9933.4437.3635.95
PS Ratio
4.734.984.904.013.814.103.764.704.934.394.574.674.994.914.723.804.624.974.875.71